JPWO2021194914A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021194914A5
JPWO2021194914A5 JP2022557736A JP2022557736A JPWO2021194914A5 JP WO2021194914 A5 JPWO2021194914 A5 JP WO2021194914A5 JP 2022557736 A JP2022557736 A JP 2022557736A JP 2022557736 A JP2022557736 A JP 2022557736A JP WO2021194914 A5 JPWO2021194914 A5 JP WO2021194914A5
Authority
JP
Japan
Prior art keywords
dione
piperidine
oxo
dihydro
isoindol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520759A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023382 external-priority patent/WO2021194914A1/en
Publication of JP2023520759A publication Critical patent/JP2023520759A/ja
Publication of JPWO2021194914A5 publication Critical patent/JPWO2021194914A5/ja
Pending legal-status Critical Current

Links

JP2022557736A 2020-03-23 2021-03-22 がん治療のための置換オキソイソインドリン化合物 Pending JP2023520759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993144P 2020-03-23 2020-03-23
US62/993,144 2020-03-23
PCT/US2021/023382 WO2021194914A1 (en) 2020-03-23 2021-03-22 Substituted oxoisoindoline compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023520759A JP2023520759A (ja) 2023-05-19
JPWO2021194914A5 true JPWO2021194914A5 (ru) 2024-04-02

Family

ID=75478287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557736A Pending JP2023520759A (ja) 2020-03-23 2021-03-22 がん治療のための置換オキソイソインドリン化合物

Country Status (13)

Country Link
US (1) US20230322803A1 (ru)
EP (1) EP4126843A1 (ru)
JP (1) JP2023520759A (ru)
KR (1) KR20220158256A (ru)
CN (1) CN115605466A (ru)
AR (1) AR121600A1 (ru)
AU (1) AU2021241458A1 (ru)
BR (1) BR112022018706A2 (ru)
CA (1) CA3172626A1 (ru)
IL (1) IL296676A (ru)
MX (1) MX2022011601A (ru)
TW (1) TW202140441A (ru)
WO (1) WO2021194914A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023020077A2 (pt) * 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
US20230242508A1 (en) * 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros鋅指家族降解劑及其用途
TW202345797A (zh) * 2022-03-25 2023-12-01 美商昂科皮治療公司亦以普羅提歐凡治療公司名稱營業 作為ikzf2降解劑之含雙環雜芳基化合物
CN114702440A (zh) * 2022-04-26 2022-07-05 永农生物科学有限公司 一种氨氯吡啶酸的制备方法及制备的氨氯吡啶酸
WO2024096753A1 (en) * 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
KR101562549B1 (ko) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
TWI382974B (zh) 2005-12-20 2013-01-21 Incyte Corp 作為吲哚胺2,3-二氧化酶調節劑之n-羥基甲脒基雜環化物
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ido阻害剤
JP2011523616A (ja) 2008-05-29 2011-08-18 サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン チタン酸アルミニウムを含有する多孔質構造体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
PE20121398A1 (es) 2009-12-10 2012-10-26 Hoffmann La Roche Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
SI2566517T1 (sl) 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
NO2694640T3 (ru) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 B7-h1 및 pd-1과 결합하는 항체 및 다른 분자들
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
JP6416630B2 (ja) 2012-02-06 2018-10-31 ジェネンテック, インコーポレイテッド Csf1r阻害剤を用いるための組成物及び方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20140079699A1 (en) 2012-08-31 2014-03-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104230787B (zh) * 2014-08-20 2016-08-24 华东师范大学 N-(1,3-二氧代异吲哚啉)芳酰胺类化合物及其制备方法和应用
IL266842B (en) * 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2021501570A (ja) * 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11192877B2 (en) * 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11548870B2 (en) * 2019-11-19 2023-01-10 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein

Similar Documents

Publication Publication Date Title
KR101491865B1 (ko) N-에틸퀴놀론 및 n-에틸아자퀴놀론의 유도체 및 유사체
AU2010311378B2 (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
JP2021518395A5 (ru)
US11713327B2 (en) Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
EP2137177B1 (en) Aurora kinase modulators and method of use
KR101110530B1 (ko) 증식성 질환의 치료에 유용한 키나제 억제제
JP6306049B2 (ja) A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物
US20210393623A1 (en) Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
KR101567096B1 (ko) 항균제로서의 트리시클릭 질소 함유 화합물
TW201940167A (zh) Shp2抑制劑及其用途
JP2016500671A5 (ru)
AU2010255727B2 (en) 1H-imidazo[4,5-c]quinolinone derivatives
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
US11820766B2 (en) Monoacylglycerol lipase modulators
JP2020510092A5 (ru)
MX2014010377A (es) Compuestos heterobiciclicos.
CA2763099A1 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
EP2303886A2 (en) Pi3k/m tor inhibitors
JPWO2021194914A5 (ru)
KR20220027871A (ko) NF-kB 유도 키나아제의 소분자 억제제
JPWO2020065613A5 (ru)
JP2009543850A (ja) N−エチルキノロンおよびn−エチルアザキノロンの誘導体およびアナログ
KR20210097148A (ko) 간질의 치료를 위한 헤테로시클릭 화합물
KR20230069169A (ko) 카제인 키나제 1 델타 조절제
JP2023508943A (ja) ジヒドロシクロペンタ-イソキノリン-スルホンアミド誘導体化合物